GNNSF
Price
$1.35
Change
+$0.06 (+4.62%)
Updated
May 12 closing price
Capitalization
3.04B
ORYZF
Price
$3.03
Change
-$0.00 (-0.00%)
Updated
May 7 closing price
Capitalization
241.92M
Interact to see
Advertisement

GNNSF vs ORYZF

Header iconGNNSF vs ORYZF Comparison
Open Charts GNNSF vs ORYZFBanner chart's image
Genscript Biotech
Price$1.35
Change+$0.06 (+4.62%)
Volume$1K
Capitalization3.04B
Oryzon Genomics SA
Price$3.03
Change-$0.00 (-0.00%)
Volume$5K
Capitalization241.92M
GNNSF vs ORYZF Comparison Chart
Loading...
View a ticker or compare two or three
VS
GNNSF vs. ORYZF commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNNSF is a Hold and ORYZF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (GNNSF: $1.36 vs. ORYZF: $3.03)
Brand notoriety: GNNSF and ORYZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNNSF: 120% vs. ORYZF: 52%
Market capitalization -- GNNSF: $3.04B vs. ORYZF: $241.92M
GNNSF [@Biotechnology] is valued at $3.04B. ORYZF’s [@Biotechnology] market capitalization is $241.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNNSF’s FA Score shows that 0 FA rating(s) are green whileORYZF’s FA Score has 1 green FA rating(s).

  • GNNSF’s FA Score: 0 green, 5 red.
  • ORYZF’s FA Score: 1 green, 4 red.
According to our system of comparison, ORYZF is a better buy in the long-term than GNNSF.

Price Growth

GNNSF (@Biotechnology) experienced а 0.00% price change this week, while ORYZF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.01%. For the same industry, the average monthly price growth was +7.65%, and the average quarterly price growth was -1.32%.

Industries' Descriptions

@Biotechnology (+5.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
GNNSF($3.04B) has a higher market cap than ORYZF($242M). ORYZF YTD gains are higher at: 87.037 vs. GNNSF (6.693). ORYZF has higher annual earnings (EBITDA): 834K vs. GNNSF (-203.82M). GNNSF has more cash in the bank: 1.87B vs. ORYZF (8.44M). ORYZF has less debt than GNNSF: ORYZF (13.4M) vs GNNSF (448M). GNNSF has higher revenues than ORYZF: GNNSF (1.01B) vs ORYZF (0).
GNNSFORYZFGNNSF / ORYZF
Capitalization3.04B242M1,255%
EBITDA-203.82M834K-24,439%
Gain YTD6.69387.0378%
P/E RatioN/AN/A-
Revenue1.01B0-
Total Cash1.87B8.44M22,199%
Total Debt448M13.4M3,343%
FUNDAMENTALS RATINGS
GNNSF: Fundamental Ratings
GNNSF
OUTLOOK RATING
1..100
44
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
40
SEASONALITY SCORE
1..100
43

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CZOVX26.27N/A
N/A
Zacks All-Cap Core Institutional
AGFGX12.14N/A
N/A
American Century Focused Global Gr R5
NQQQX39.74N/A
N/A
Shelton Nasdaq-100 Index Institutional
NPNRX46.50N/A
N/A
Neuberger Berman Large Cap Value R3
ADOZX22.19N/A
N/A
Alger Dynamic Opportunities Z

GNNSF and

Correlation & Price change

A.I.dvisor tells us that GNNSF and ORYZF have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNNSF and ORYZF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNNSF
1D Price
Change %
GNNSF100%
N/A
ORYZF - GNNSF
24%
Poorly correlated
N/A
ARGNF - GNNSF
23%
Poorly correlated
N/A
CLDI - GNNSF
23%
Poorly correlated
-9.15%
PRLD - GNNSF
20%
Poorly correlated
-6.91%
HNSBF - GNNSF
17%
Poorly correlated
N/A
More

ORYZF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORYZF has been loosely correlated with CLDI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORYZF jumps, then CLDI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORYZF
1D Price
Change %
ORYZF100%
N/A
CLDI - ORYZF
37%
Loosely correlated
-9.15%
PPBT - ORYZF
28%
Poorly correlated
-1.66%
DRUG - ORYZF
25%
Poorly correlated
-6.25%
GNNSF - ORYZF
24%
Poorly correlated
N/A
IPSC - ORYZF
20%
Poorly correlated
-3.40%
More